Table 1 Elesclomol-related clinical trials
From: Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy
Clinical Trial Subjects | Staging of Clinical Trials | Recruitment Status | Drug use | Results | References |
|---|---|---|---|---|---|
Acute myeloid leukemia | Phase I | Unknown | Elesclomol sodium | Elesclomol has a good clinical safety profile, but patients have not developed clinical responses to elesclomol | 26732437 |
Solid tumors | Phase I | Completed | Elesclomol sodium, Paclitaxel | The combination of Elesclomol and paclitaxel was well tolerated by patients and the toxicity profile of elesclomol was similar to that of single agent paclitaxel | 17255281 |
Melanoma | Phase I/II | Completed | Elesclomol sodium, Paclitaxel | The combination of elesclomol and paclitaxel resulted in a statistically significant doubling of median PFS, with an acceptable toxicity profile and encouraging OS | 19826135 |
Melanoma | Phase III | Terminated | Elesclomol sodium, Paclitaxel | The combination of elesclomol and paclitaxel did not significantly improve PFS | 23401447 |
Recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, primary peritoneal cancer | Phase II | Completed | Elesclomol sodium, Paclitaxel | The combination of elesclomol and paclitaxel was well tolerated by patients but the proportion responding was low | 30309721 |
Solid tumors | Phase I | Suspended | Elesclomol sodium | Unpublished | - |
Prostate cancer | Phase I | Completed | Elesclomol sodium, Docetaxel | Unpublished | - |
Stage IIIB/IV non-small cell lung cancer | Phase I/II | Completed | Elesclomol sodiuml, Paclitaxel, Carboplatin | Unpublished | - |
Soft tissue sarcoma | Phase II | Completed | Elesclomol sodium, taxane | Elesclomol enhanced taxane efficacy by induction of Hsp70 | 16784029 |